Abstract:Although impactful scientific advancements have recently been made in cancer therapy, there remains an opportunity for future improvements. Immunotherapy is perhaps one of the most cutting-edge categories of therapies demonstrating potential in the clinical setting. Genetically engineered T cells express chimeric antigen receptors (CARs), which can detect signals expressed by the molecules present on the surface of cancer cells, also called tumor-associated antigens (TAAs). Their effectiveness has been extensively demonstrated in hematological cancers; therefore, these results can establish the groundwork for their applications on a wide range of requirements. However, the application of CAR-T cell technology for solid tumors has several challenges, such as the existence of an immune-suppressing tumor microenvironment and/or inadequate tumor infiltration. Consequently, combining therapies such as CAR-T cell technology with other approaches has been proposed. The effectiveness of combining CAR-T cell with oncolytic virus therapy, with either genetically altered or naturally occurring viruses, to target tumor cells is currently under investigation, with several clinical trials being conducted. This narrative review summarizes the current advancements, opportunities, benefits, and limitations in using each therapy alone and their combination. The use of oncolytic viruses offers an opportunity to address the existing challenges of CAR-T cell therapy, which appear in the process of trying to overcome solid tumors, through the combination of their strengths. Additionally, utilizing oncolytic viruses allows researchers to modify the virus, thus enabling the targeted delivery of specific therapeutic agents within the tumor environment. This, in turn, can potentially enhance the cytotoxic effect and therapeutic potential of CAR-T cell technology on solid malignancies, with impactful results in the clinical setting.

Bioorthogonal Oncolytic-Virus Nanovesicles Combined Bio-Immunotherapy with CAR-T Cells for Solid Tumors.

Oncolytic virus enhanced CAR T cell therapy in killing solid tumors

Oncolytic virus–mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice

Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy

Combining Oncolytic Viruses with Chimeric Antigen Receptor T Cell Therapy

Chimeric antigen receptor–engineered T cells as oncolytic virus carriers

Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment

Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumors

Enhancing Cancer Immunotherapy: A Novel Approach through the Integration of Oncolytic Virotherapy with CAR-T and NK Cell Therapies

Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment

Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors

Tumor Cell Membrane Biomimetic Liposomes-Coated Oncolytic Viruses to Target the Homotypic Tumor and Augment the Antitumor Efficacy

Systemic delivery of oncolytic herpes virus using CAR-T cells enhances targeting of antitumor immuno-virotherapy

An oncolytic virus–T cell chimera for cancer immunotherapy

Oncolytic adenovirus-mediated expression of CCL5 and IL12 facilitates CA9-targeting CAR-T therapy against renal cell carcinoma

Oncolytic Viruses as Reliable Adjuvants in CAR-T Cell Therapy for Solid Tumors

Augmenting Tumor Lysis and Immune Response through HIFU-armed Oncolytic Virus Delivery System

Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy

Nanoengineering-armed oncolytic viruses drive antitumor response: progress and challenges

Application of oncolytic virus in tumor therapy

The emerging field of oncolytic virus-based cancer immunotherapy